News

We’ll be taking the stage in the Healthcare Track, sharing our vision for precision hemoglobin and blood analysis with investors, industry leaders, and innovators shaping the future of healthcare. This …

Over the weekend, OxyDial stood beside an incredible community – people living with sickle cell disease, caregivers, advocates, and partners – united under one purpose: to raise awareness, share real …

Last week, we had the privilege of attending the Society for the Advancement of Patient Blood Management, Inc. (SABM) Annual Meeting. We were deeply inspired by the presentations from leading …

Fulcrum Therapeutics presented compelling Phase 1B data for its lead candidate, Posiradir, at the H.C. Wainwright Conference, underscoring its potential as a novel oral treatment for sickle cell disease (SCD). …

Sanofi has achieved a significant milestone with the FDA approval of Wayrilz (rilzabrutinib) for immune thrombocytopenia (ITP), marking it as the first Bruton’s tyrosine kinase (BTK) inhibitor approved for this …

Oryzon Genomics SA has received approval from the European Medicines Agency to initiate its Phase 1b RESTORE trial for iadademstat in patients with sickle cell disease (SCD). The trial will …

AstraZeneca has cleared a major hurdle with China’s approval of its $160 million acquisition of FibroGen, Inc.’s China unit. This strategic move grants AstraZeneca full regional rights to the anemia …

FibroGen, Inc. and Astellas Pharma have reached a milestone with the FDA’s green light to advance roxadustat into Phase 3 trials for anemia in lower-risk myelodysplastic syndromes (LR-MDS). This oral …

Agios Pharmaceuticals has made history with the first-ever regulatory approval of PYRUKYND® (mitapivat) for thalassemia, granted by Saudi Arabia’s SFDA – هيئة الغذاء والدواء under its Breakthrough Medicines Program. This …